X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA WYETH LTD ALEMBIC PHARMA/
WYETH LTD
 
P/E (TTM) x 28.4 27.7 102.5% View Chart
P/BV x 6.5 5.3 121.2% View Chart
Dividend Yield % 0.7 1.3 57.1%  

Financials

 ALEMBIC PHARMA   WYETH LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
WYETH LTD
Mar-13
ALEMBIC PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs7921,044 75.8%   
Low Rs443818 54.2%   
Sales per share (Unadj.) Rs167.0298.6 55.9%  
Earnings per share (Unadj.) Rs38.257.2 66.7%  
Cash flow per share (Unadj.) Rs42.058.4 71.9%  
Dividends per share (Unadj.) Rs4.0017.00 23.5%  
Dividend yield (eoy) %0.61.8 35.5%  
Book value per share (Unadj.) Rs84.9249.5 34.0%  
Shares outstanding (eoy) m188.5222.72 829.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.73.1 118.5%   
Avg P/E ratio x16.216.3 99.4%  
P/CF ratio (eoy) x14.715.9 92.2%  
Price / Book Value ratio x7.33.7 194.8%  
Dividend payout %10.529.7 35.3%   
Avg Mkt Cap Rs m116,38321,157 550.1%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m4,214400 1,053.5%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m31,4876,783 464.2%  
Other income Rs m55353 15.6%   
Total revenues Rs m31,5427,136 442.0%   
Gross profit Rs m10,0601,617 622.0%  
Depreciation Rs m72227 2,714.7%   
Interest Rs m376 669.1%   
Profit before tax Rs m9,3561,938 482.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m2,160632 341.7%   
Profit after tax Rs m7,1941,301 553.2%  
Gross profit margin %31.923.8 134.0%  
Effective tax rate %23.132.6 70.8%   
Net profit margin %22.819.2 119.2%  
BALANCE SHEET DATA
Current assets Rs m15,0666,984 215.7%   
Current liabilities Rs m7,6742,056 373.3%   
Net working cap to sales %23.572.6 32.3%  
Current ratio x2.03.4 57.8%  
Inventory Days Days6799 67.5%  
Debtors Days Days4124 169.7%  
Net fixed assets Rs m8,237244 3,371.9%   
Share capital Rs m377227 165.9%   
"Free" reserves Rs m15,4165,441 283.3%   
Net worth Rs m16,0055,668 282.4%   
Long term debt Rs m025 0.0%   
Total assets Rs m24,5947,901 311.3%  
Interest coverage x255.2353.3 72.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.9 149.1%   
Return on assets %29.416.5 177.9%  
Return on equity %44.922.9 195.9%  
Return on capital %58.734.0 172.3%  
Exports to sales %55.70.2 25,547.6%   
Imports to sales %10.436.3 28.7%   
Exports (fob) Rs m17,55115 118,586.5%   
Imports (cif) Rs m3,2832,465 133.2%   
Fx inflow Rs m17,81115 117,174.3%   
Fx outflow Rs m5,3182,677 198.6%   
Net fx Rs m12,493-2,662 -469.3%   
CASH FLOW
From Operations Rs m9,304923 1,007.8%  
From Investments Rs m-3,105317 -979.7%  
From Financial Activity Rs m-1,959-481 407.3%  
Net Cashflow Rs m4,240759 558.6%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 2.9 11.3 25.7%  
FIIs % 9.1 7.2 126.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 30.4 45.7%  
Shareholders   49,328 21,978 224.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS